Actions Taken by the Medical Advisory Panel

The following Assessments were acted on at the October 1, 2009, Blue Cross and Blue Shield Association Medical Advisory Panel (MAP) meeting:

Carotid Artery Angioplasty and Stenting

The MAP concluded that use of carotid artery angioplasty and stenting with embolic protection of the cerebral circulation for patients with carotid artery stenosis does not meet the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC) criteria.

Pharmacogenetic Testing to Predict Serious Toxicity from 5-Fluorouracil (5-FU) for Patients Administered 5-FU-Based Chemotherapy for Cancer

The MAP concluded that the use of pharmacogenetic testing to predict serious toxicity from 5-FU for patients administered 5-FU-based  chemotherapy for cancer does not meet the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC) criteria.

Special Report: Vaccines for the Treatment of Prostate Cancer

The MAP voted to approve the conclusions and publication of this draft Special Report.

The MAP voted to table the topic "Laboratory Testing to Allow Area Under the Curve (AUC)-Targeted 5-Fluorouracil Dosing for Patients Administered Chemotherapy for Cancer."